For much of the past two decades, progress in genomic medicine has been measured by technical achievement. Sequencing technologies became faster, databases grew larger, bioinformatics pipelines more sophisticated, and diagnostic yields steadily improved.
These advances transformed the ability of clinicians and laboratories to identify the genetic causes of rare and complex conditions. Yet, despite these achievements, an important question remains largely unanswered: what happens after a genomic answer is found?
A genetic diagnosis is often treated as the endpoint of a successful clinical journey. In reality, it is usually the beginning of a much longer one. Families leave clinics carrying new information, new uncertainties, and new decisions. They are expected to understand unfamiliar scientific concepts, communicate results to relatives, and navigate healthcare systems. They must make choices about treatment, surveillance, reproduction, and future planning.
The technical report may be complete. The patient’s journey is not.
Unanswered questions
I encountered this gap directly in my work in clinical genomics and molecular diagnostics. A family who had waited nearly three years for a diagnosis received their result on a Sunday afternoon. The variant was classified. The report was accurate.
By Tuesday, they had sent eleven messages to the clinic – not about the science, but about what to tell the school, whether to test the siblings, and whether the diagnosis would affect their insurance. The report had answered the genetic question. It had not prepared them for what came next.
This is not an isolated experience. Laboratories routinely monitor quality indicators such as turnaround time, sequencing coverage, and diagnostic yield. These measures are essential. But they tell us very little about whether patients understood their results, whether expectations were aligned with reality, or whether recommended follow-up actually happened.
There is a real distance between the moment a result is issued and the moment it becomes meaningful to the person receiving it. For laboratories, the challenge is no longer simply generating accurate results, but ensuring those results can be translated into informed decisions and meaningful care.
The challenge extends beyond patients and families. Many healthcare professionals now encounter genomic information in routine practice but have received limited formal training in how to interpret, communicate, and apply these findings.
Understanding as standard
That distance grows more significant as genomics moves into an increasingly interventional era. Advances in gene therapy, RNA-based therapeutics, and precision medicine are changing what a genetic diagnosis means. For some conditions, identifying a pathogenic variant is no longer the end of the process. It is the beginning of a therapeutic pathway, and that shift carries new responsibilities for everyone involved.
Families are now exposed to information about emerging treatments, clinical trials, and future possibilities before those possibilities are ready for them. Hope becomes part of the clinical conversation. That is not a bad thing. But hope without context can lead to confusion, misaligned expectations, and real emotional burden.
The challenge is not simply explaining what is scientifically possible. It is helping patients and families understand what is available, accessible, and relevant to their situation right now.
This experience has led me to view communication, education, and storytelling as integral components of genomic care rather than optional additions to it. Quality in this field cannot be measured by technical performance alone. It also lives in whether people understood what they were told, whether they felt supported in making decisions, and whether the care they received reflected some awareness of the life they were returning to after the appointment.
The wider conversation
Scientific knowledge and lived experience have too often been treated as separate concerns. Patients, families, clinicians, laboratory professionals, counselors, educators, and advocates all carry different parts of the same story. When those perspectives come together, they reveal things that data alone does not show: where communication breaks down, where expectations diverge, and where people fall through the gaps between what the system offers and what they actually need.
The field is moving quickly. As genomic testing becomes more accessible, and therapeutic options continue to grow, the work of connecting scientific progress to human experience becomes more urgent, not less. What is measured, communicated, and prioritized in the clinic and the laboratory will shape whether that progress reaches people in ways that are genuinely useful to them.
Policy plays an equally important role. Decisions about coverage, reimbursement, genetic privacy, and research funding matter. They determine not only who can access genomic medicine but how much space exists within it for education, counseling, and follow-up care.
These conversations should not be held separate from the science. They are part of what makes the science matter.
The variants are just the beginning
In many Middle Eastern settings, these challenges are further shaped by limited access to genetic counseling, variable insurance coverage, cultural stigma surrounding inherited conditions, and uneven availability of advanced therapies or clinical trials. In such contexts, genomic care cannot rely on testing alone. It requires culturally sensitive education, stronger clinician support, and policies that make follow-up care, counseling, and family communication more accessible.
Genomic medicine has always been about more than identifying variants. It is about helping people make sense of information that can change how they understand themselves, their families, and their futures. As the field enters a new era of therapeutic possibility, success will depend not only on what we discover in the genome, but on how effectively we translate those discoveries into understanding, action, and care.
The future of genomics will be shaped not only by the variants we identify, but by the voices we learn to hear.
Newsletters
Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.
